Search Results - Ros Cutts

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial

    Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial by Sarah Hrebien, Valentina Citi, Isaac García-Murillas, Ros Cutts, Kerry Fenwick, Iwanka Kozarewa, Robert McEwen, Jayantha Ratnayake, Rhiannon Maudsley, T. Hedley Carr, Elza C. de Bruin, Gaia Schiavon, Mafalda Oliveira, Nicholas C. Turner

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer

    Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer by Uzma Asghar, Alexis R. Barr, Ros Cutts, Matthew Beaney, Irina S. Babina, Deepak Sampath, Jennifer M. Giltnane, Jennifer A. Lacap, Lisa Crocker, Amy Young, Alex Pearson, María Teresa Herrera-Abreu, Chris Bakal, Nicholas C. Turner

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

    Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer by Neha Chopra, Holly Tovey, Alex Pearson, Ros Cutts, Christy Toms, Paula Proszek, Michael Hubank, Mitch Dowsett, Andrew Dodson, Frances Daley, Divya Kriplani, Heidi Gevensleben, Helen Davies, Andrea Degasperi, Rebecca Roylance, Stephen Chan, Andrew Tutt, Anthony Skene, Abigail Evans, Judith M. Bliss, Serena Nik‐Zainal, Nicholas C. Turner

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    High-Level Clonal <i>FGFR</i> Amplification and Response to FGFR Inhibition in a Translational Clinical Trial

    High-Level Clonal <i>FGFR</i> Amplification and Response to FGFR Inhibition in a Translational Clinical Trial by Alex Pearson, Elizabeth Smyth, Irina S. Babina, María Teresa Herrera-Abreu, Noelia Tarazona, Clare Peckitt, Elaine Kilgour, Neil R. Smith, Catherine Geh, Claire Rooney, Ros Cutts, James Campbell, Jian Ning, Kerry Fenwick, Amanda Swain, Gina Brown, Sue Chua, Anne Thomas, Stephen R.D. Johnston, Mazhar Ajaz, Katherine Sumpter, Angela Gillbanks, David Watkins, Ian Chau, Sanjay Popat, David Cunningham, Nicholas C. Turner

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Diverse <i>BRCA1</i> and <i>BRCA2</i> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer

    Diverse <i>BRCA1</i> and <i>BRCA2</i> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer by Britta Weigelt, Iñaki Comino‐Méndez, Ino de Bruijn, Lei Tian, Jane Meisel, Isaac García-Murillas, Charlotte Fribbens, Ros Cutts, Luciano G. Martelotto, Charlotte K.Y. Ng, Raymond S. Lim, Pier Selenica, Salvatore Piscuoglio, Carol Aghajanian, Larry Norton, Rajmohan Murali, David M. Hyman, Laetitia Borsu, Maria E. Arcila, Jason Konner, Jorge S. Reis‐Filho, Roger A. Greenberg, Mark E. Robson, Nicholas C. Turner

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

    Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial by Nicholas C. Turner, Belinda Kingston, Lucy Kilburn, Sarah Kernaghan, Andrew Wardley, Iain R. Macpherson, Richard D. Baird, Rebecca Roylance, Peter Stephens, Olga Oikonomidou, Jeremy Braybrooke, Mark Tuthill, Jacinta Abraham, Matthew Winter, Hannah Bye, Michael Hubank, Heidrun Gevensleben, Ros Cutts, Claire Snowdon, Daniel Rea, David Cameron, Abeer M. Shaaban, Katrina Randle, Sue Martin, Katie Wilkinson, Laura Moretti, Judith M. Bliss, Alistair Ring

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer

    Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer by María Teresa Herrera-Abreu, Jingwen Guan, Usman Khalid, Jian Ning, Márcia Regina da Costa, Jason Yongsheng Chan, Qing Li, Jessyka Fortin, WS Wong, Pirunthan Perampalam, A. Biton, Wendy Sandoval, Jyothi Vijay, Marc Hafner, Ros Cutts, Gerald M. Wilson, Jessica Frankum, Theodoros I. Roumeliotis, John Alexander, Oliver Hickman, Rachel Brough, Syed Haider, Jyoti S. Choudhary, Christopher J. Lord, Amanda Swain, Ciara Metcalfe, Nicholas C. Turner

    Published 2024
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: